Kura Oncology to Join Bank of America 2024 Healthcare Conference

28 June 2024

Kura Oncology, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker symbol KURA, is committed to advancing precision medicines for cancer treatment. On May 8, 2024, the company announced its participation in the upcoming Bank of America Securities 2024 Healthcare Conference. Troy Wilson, Ph.D., J.D., the President and CEO of Kura Oncology, will take part in a virtual fireside chat at 1:40 p.m. ET / 10:40 a.m. PT on May 15, 2024. The live audio webcast of this discussion will be accessible through the Investors section of Kura’s website, where an archived replay will also be available following the event.

Kura Oncology focuses on developing small molecule drug candidates designed to target specific cancer signaling pathways. One of the leading drugs in their pipeline is Ziftomenib, an oral drug taken once daily, which targets the menin-KMT2A protein-protein interaction. This candidate has received Breakthrough Therapy Designation for treating relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). The company is actively enrolling patients for a Phase 2 registration-directed trial known as KOMET-001, which aims to evaluate the efficacy of Ziftomenib in NPM1-mutant R/R AML. 

In addition to this, Kura Oncology is conducting various clinical studies to assess the potential of Ziftomenib in combination with existing standards of care for treating newly diagnosed and relapsed or refractory AML in cases of both NPM1 mutations and KMT2A rearrangements. 

Another significant drug in Kura’s pipeline is Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI). This drug is currently in a Phase 1/2 trial, where it is being tested in combination with alpelisib for patients suffering from PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC), in a study called KURRENT-HN. 

Furthermore, Kura Oncology is evaluating KO-2806, a next-generation FTI, through a Phase 1 dose-escalation trial. This trial is designed to test KO-2806 both as a monotherapy and in combination with other targeted therapies under the program named FIT-001.

The company’s dedication to specialized cancer treatments underscores its strategic approach to addressing complex cancer types with precision medicines. Through its robust pipeline, Kura Oncology aims to bring forward transformative therapies that could offer hope and improved outcomes for patients battling various forms of cancer. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!